No Washout Period Required When Switching from Enoxaparin to Apixaban
Start apixaban at the time the next enoxaparin dose would have been due—no washout period is needed. If enoxaparin was given in the morning, you can initiate apixaban that same afternoon or evening when the next enoxaparin dose would be scheduled 1.
Practical Transition Strategy
The FDA label for apixaban explicitly addresses this transition scenario from the ADVANCE trials, where apixaban was initiated 12-24 hours after the last enoxaparin dose without safety concerns 1. This timing aligns with enoxaparin's pharmacokinetic profile:
- Enoxaparin half-life: ~4-5 hours with therapeutic dosing
- Anti-Xa activity: Substantially diminished by 12 hours, nearly absent by 24 hours
- Apixaban onset: Reaches therapeutic levels within 3-4 hours of first dose
Specific Timing Recommendations
For a patient on twice-daily enoxaparin (e.g., 1 mg/kg BID):
- Give the morning enoxaparin dose as scheduled
- Skip the evening enoxaparin dose
- Start apixaban at the time the evening enoxaparin would have been due (typically 12 hours later)
For a patient on once-daily enoxaparin (e.g., 1.5 mg/kg daily):
- Give the morning enoxaparin dose
- Start apixaban 12-24 hours later (that afternoon/evening or next morning)
Critical Considerations
Renal function matters: In patients with CrCl 15-30 mL/min, enoxaparin clearance is significantly prolonged. Consider waiting closer to 24 hours before starting apixaban in this population 2.
Avoid overlap: Unlike warfarin transitions that require co-administration, do not give enoxaparin and apixaban simultaneously. The combination increases bleeding risk without additional thrombotic protection.
No bridging gap needed: The 12-24 hour transition window from enoxaparin to apixaban does not create a clinically significant anticoagulation gap for AFib stroke prevention. The thrombotic risk during this brief period is negligible compared to the bleeding risk of overlapping agents.
Common Pitfall to Avoid
The most frequent error is unnecessarily prolonging enoxaparin or creating an anticoagulation gap by waiting too long. The ACCP perioperative guidelines confirm that therapeutic LMWH effects are minimal beyond 24 hours, and most patients have subtherapeutic anti-Xa levels by 12 hours 3. Starting apixaban at the next scheduled enoxaparin time maintains continuous anticoagulation without excessive overlap.